scholarly journals Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson’s Disease

2018 ◽  
Vol 8 (s1) ◽  
pp. S65-S72 ◽  
Author(s):  
Daniel J. van Wamelen ◽  
Sotirios Grigoriou ◽  
K. Ray Chaudhuri ◽  
Per Odin
Keyword(s):  
Parkinson’S Disease ◽  
Drug Delivery ◽  
Parkinson's Disease ◽  
Continuous Dopaminergic Stimulation ◽  
Continuous Drug Delivery ◽  
Dopaminergic Stimulation

Continuous Dopaminergic Stimulation in Parkinson's Disease - What Have We Learned from Positron-emission Tomography?

2010 ◽  
Vol 5 (1) ◽  
pp. 22
Author(s):  
David J Brooks ◽  
Nicola Pavese ◽  
◽  
Keyword(s):  
Parkinson’S Disease ◽  
Positron Emission Tomography ◽  
Parkinson's Disease ◽  
Monoamine Oxidase Inhibitor ◽  
Oxidase Inhibitor ◽  
Emission Tomography ◽  
Continuous Dopaminergic Stimulation ◽  
Positron Emission ◽  
Significant Step ◽  
Dopaminergic Stimulation

The hypothesis that pulsatile stimulation of striatal dopamine receptors in Parkinson's disease (PD) induces molecular and physiological changes in basal ganglia neurons and may contribute to the development of motor complications has led to the design of therapeutic strategies that provide more continuous dopaminergic stimulation. Newer agents and drug-delivery systems, such as slow-release preparations, catechol- O-methyltransferase and monoamine oxidase inhibitor agents, apomorphine and Duodopa™infusions, represent a significant step towards less pulsatile dopaminergic administration. However, their efficacy in providing steady brain levels of dopaminergic stimulation in the short and longer term has not yet been proved in patients. This article briefly reviews and discusses the findings of published positron-emission tomography (PET) studies that support or oppose the value of continuous dopaminergic stimulation in PD. The potential future value of PET for proof of mechanism in this area is also debated.

Rotigotine for the Treatment of Advanced Parkinson's Disease

2009 ◽  
Vol 4 (2) ◽  
pp. 24
Author(s):  
Santiago Perez Lloret ◽  
Olivier Rascol ◽  
◽  
Keyword(s):  
Parkinson’S Disease ◽  
Drug Delivery ◽  
Parkinson's Disease ◽  
Clinical Efficacy ◽  
Transdermal Patch ◽  
Motor Complications ◽  
Once Daily ◽  
Rotigotine Patch ◽  
Continuous Drug Delivery ◽  
Rotigotine Transdermal Patch

Background: Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch is approved by the regulatory authorities for use in all stages of Parkinson’s disease (PD) in Europe and for early-stage PD in the US. For patients with advanced-stage PD and motor fluctuations, approved doses range from 4mg/24 hours to 16mg/24 hours. The rotigotine patch offers a certain number of potential advantages, including faster onset as intestinal absorption is not needed, continuous drug delivery and ease of use via application of a once-daily adhesive patch. An interesting element of this profile is continuous drug delivery, which may avoid the pulsatile dopaminergic stimulation that has been postulated to be related to the development of motor complications.Objective: The aim of this article is to review the pharmacokinetics, pharmacodynamics and clinical efficacy and tolerability of the rotigotine transdermal patch.Methods: Source material was identified using a PubMed search for the term ‘rotigotine’ in articles published up to October 2009 and a review of published congress abstracts. The review focused primarily on publications related to the rotigotine indication for advanced PD.Results and conclusions: The rotigotine transdermal patch demonstrates clinical efficacy and a tolerability profile that appears to be well within the range of that observed with other non-ergot dopamine agonists, except for local skin reactions, which are common with the rotigotine patch. The once-daily patch formulation may encourage compliance; however, as is the case for other theoretical advantages of continuous drug delivery, such as reduced emergence of motor complications and improved tolerance of peripheral adverse events, this requires further detailed study.

Sign in / Sign up

Export Citation Format

Share Document